Increasing NAD+ levels by supplementing with the precursor nicotinamide mononucleotide (NMN) improves cardiac function in multiple mouse models of disease. While NMN influences several aspects of mitochondrial metabolism, the molecular mechanisms by which increased NAD+ enhances cardiac function are poorly understood. A putative mechanism of NAD+ therapeutic action exists via activation of the mitochondrial NAD+-dependent protein deacetylase sirtuin 3 (SIRT3). We assessed the therapeutic efficacy of NMN and the role of SIRT3 in the Friedreich's ataxia cardiomyopathy mouse model (FXN-KO). At baseline, the FXN-KO heart has mitochondrial protein hyperacetylation, reduced Sirt3 mRNA expression, and evidence of increased NAD+ salvage. Remarkably, NMN administered to FXN-KO mice restores cardiac function to near-normal levels. To determine whether SIRT3 is required for NMN therapeutic efficacy, we generated SIRT3-KO and SIRT3-KO/FXN-KO (double KO [dKO]) models. The improvement in cardiac function upon NMN treatment in the FXN-KO is lost in the dKO model, demonstrating that the effects of NMN are dependent upon cardiac SIRT3. Coupled with cardio-protection, SIRT3 mediates NMN-induced improvements in both cardiac and extracardiac metabolic function and energy metabolism. Taken together, these results serve as important preclinical data for NMN supplementation or SIRT3 activator therapy in Friedreich's ataxia patients.
Keywords: Cardiology; Metabolism.
Conflict of interest statement
Progressive mitochondrial protein lysine acetylation and heart failure in a model of Friedreich's ataxia cardiomyopathy.PLoS One. 2017 May 25;12(5):e0178354. doi: 10.1371/journal.pone.0178354. eCollection 2017. PLoS One. 2017. PMID: 28542596 Free PMC article.
The potential of the novel NAD+ supplementing agent, SNH6, as a therapeutic strategy for the treatment of Friedreich's ataxia.Pharmacol Res. 2020 May;155:104680. doi: 10.1016/j.phrs.2020.104680. Epub 2020 Feb 4. Pharmacol Res. 2020. PMID: 32032665
Friedreich's ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase.Hum Mol Genet. 2012 Jun 15;21(12):2688-97. doi: 10.1093/hmg/dds095. Epub 2012 Mar 6. Hum Mol Genet. 2012. PMID: 22394676 Free PMC article.
NAD+ precursor modulates post-ischemic mitochondrial fragmentation and reactive oxygen species generation via SIRT3 dependent mechanisms.Exp Neurol. 2020 Mar;325:113144. doi: 10.1016/j.expneurol.2019.113144. Epub 2019 Dec 16. Exp Neurol. 2020. PMID: 31837320 Review.
[The pathophysiological importance and therapeutic potential of NAD' biosynthesis and mitochondrial sirtuin SIRT3 in age-associated diseases].Nihon Rinsho. 2016 Sep;74(9):1447-1455. Nihon Rinsho. 2016. PMID: 30557475 Review. Japanese.
Cited by 19 articles
Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD+ Metabolism.Front Cell Dev Biol. 2020 Apr 28;8:246. doi: 10.3389/fcell.2020.00246. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32411700 Free PMC article. Review.
NAD(H) in mitochondrial energy transduction: implications for health and disease.Curr Opin Physiol. 2018 Jun;3:101-109. doi: 10.1016/j.cophys.2018.03.011. Epub 2018 Apr 11. Curr Opin Physiol. 2018. PMID: 32258851 Free PMC article.
Investigating RNA expression profiles altered by nicotinamide mononucleotide therapy in a chronic model of alcoholic liver disease.Hum Genomics. 2019 Dec 10;13(1):65. doi: 10.1186/s40246-019-0251-1. Hum Genomics. 2019. PMID: 31823815 Free PMC article.
Disruption of Acetyl-Lysine Turnover in Muscle Mitochondria Promotes Insulin Resistance and Redox Stress without Overt Respiratory Dysfunction.Cell Metab. 2020 Jan 7;31(1):131-147.e11. doi: 10.1016/j.cmet.2019.11.003. Epub 2019 Dec 5. Cell Metab. 2020. PMID: 31813822
Unlocking the Secrets of Mitochondria in the Cardiovascular System: Path to a Cure in Heart Failure—A Report from the 2018 National Heart, Lung, and Blood Institute Workshop.Circulation. 2019 Oct 1;140(14):1205-1216. doi: 10.1161/CIRCULATIONAHA.119.040551. Circulation. 2019. PMID: 31769940
- K08 HL125905/HL/NHLBI NIH HHS/United States
- T32 GM007184/GM/NIGMS NIH HHS/United States
- P30 DK096493/DK/NIDDK NIH HHS/United States
- R00 CA168997/CA/NCI NIH HHS/United States
- F31 HL123275/HL/NHLBI NIH HHS/United States